Crown Bioscience Inc.
Crown Bioscience Showcases Dramatic Proficiency in PDX Models and Emerging Expertise in Immune-Oncology
Post AACR Immuno-Oncology Scientific Advancements
SANTA CLARA, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces depth and breadth of technologies that ignite and accelerate the development of new immune-oncology drug discovery.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/71dfadf0-8256-43cd-bafb-c429a8d37457
CrownBio scientific contribution to AACR:
- Technology which engrafts human immune cells into immunocompromised animals. When tested with immune activating agents, both short-term (PBMC) and long-term (CD34+ stem cell) engraftment strategies demonstrate robust anticancer activity.
- Syngeneic models - both in vitro
and in vivo
data utilizing their MuScreen(TM) platform, a large panel of well-characterized and validated syngeneic models, employed to test the activity of immune modulating anticancer drugs.
- Utilization of RNASeq data providing expression and mutation data from 18 cell lines. Investigators leverage this data to test both targeted therapy and immune-modulatory therapy in combination, thus providing rationale for clinical investigation.
- In vivo , the MuScreen platform enables an agnostic investigation of a compound's activity and mechanism of action. MuScreen data can be followed-up with additional pharmacology studies, such as immunophenotyping, or bioluminescent assessment of metastatic burden.
"Our diligent focus on innovation, and continued scientific advancement charter unprecedented discovery in our immuno-oncology portfolio," said Jean-Pierre Wery, CEO of CrownBio. "The robust contribution at this year's annual meeting of the American Association for Cancer Research, on the part of our scientific team, validates an unwavering commitment to develop therapies that will impact the way cancer is treated."
CrownBio can be located at ASCO Booth #17071. To schedule a meeting with our scientific leadership visit: https://www.crownbio.com/asco-meeting-req
For more information on CrownBio's commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com .
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. firstname.lastname@example.org
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Oxford Immunotec15.12.2017 22:06 | pressemeddelelse
Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit
Algeco Scotsman15.12.2017 21:34 | pressemeddelelse
Algeco Scotsman Announces Acquisition of Iron Horse Ranch
Elemica15.12.2017 13:57 | pressemeddelelse
Elemica Named to Food Logistics Top 100 List
GSV Asset Management14.12.2017 21:05 | pressemeddelelse
GSV Asset Management Announces Strategic Investment from HMC Capital-Led Group
TrueCommerce14.12.2017 19:30 | pressemeddelelse
TrueCommerce Datalliance Releases Third 2017 Update for Vendor Managed Inventory Platform
ATTO Technology, Inc.14.12.2017 18:39 | pressemeddelelse
ATTO announces support for Apple® Release of the new iMac Pro
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum